Company intelligence / Profile preview

BEKS

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

BEKS Therapeutics is a South Korean biotechnology company specializing in the discovery and development of novel small molecule therapeutics. The company utilizes its proprietary "BEKS-Platform," which integrates binding-site evaluation and kinase-focused screening to identify high-affinity leads for challenging biological targets. Its primary research focus includes the Hippo signaling pathway and kinase-mediated fibrotic diseases. Currently, the company's pipeline is centered on MAP4K4 inhibitors for fibrosis and TEAD inhibitors for oncology, with programs primarily in the pre-clinical stage.

Therapeutic areas: OncologyOtherGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on BEKS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BEKS.

Explore the full profile